scientific program • symposia - American Society for Reproductive ...

P-306 ANTI MULLERIAN HORMONE SERUM LEVELS
AND REPRODUCTIVE OUTCOME ARE NOT AFFECTED BY
METHOTREXATE OR LAPAROSCOPIC SALPINGECTOMY FOR THE
TREATMENT OF ECTOPIC PREGNANCY IN IVF PATIENTS.
T. Singer 1 , J. Kofinas 1 , J. Huang 1 , R. Elias 1 , H.-C. Liu 1 , G. L. Schattman 1 ,
Z. Rosenwaks 2 . 1 The Center for Reproductive Medicine and Infertility,
New York, NY; 2 The Ronald O. Perelman & Claudia Cohen Center for
Reproductive Medicine, Weill Cornell Medical College, New York, NY.
P-307 THE ASSOCIATION OF URINARY PARABEN
CONCENTRATIONS WITH MEASURES OF OVARIAN RESERVE
AMONG PATIENTS FROM A FERTILITY CENTER.
K. W. Smith 1 , I. Dimitriadis 1,2 , S. Ehrlich 1 , J. Ford 1 , K. F. Berry 3 , I. Souter 2 .
1 Environmental Health, Harvard School of Public Health, Boston, MA;
2 Obstetrics, Gynecology & Reproductive Biology, Massachusetts
General Hospital - Harvard Medical School, Boston, MA; 3Obstetrics
and Gynecology, Brigham and Women’s Hospital, Boston, MA.
P-308 REPETITIVE OVARIAN RESERVE TESTING AS A MEASURE
OF NATURAL FECUNDABILITY.
A. Z. Steiner 1 , D. L. Long 2 , A. H. Herring 2 . 1 Obstetrics and Gynecology,
University of North Carolina, Chapel Hill, NC; 2 Biostatistics, University
of North Carolina, Chapel Hill, NC.
P-309 FERTILITY-RELATED STRESS IN WOMEN WITH
DIMINISHED OVARIAN RESERVE UNDERGOING FRAGILE X
GENETIC TESTING.
A. K. Schutt, L. M. Pastore. Obstetrics and Gynecology, University of
Virginia, Charlottesville, VA.
P-310 COMPARISON OF AGE-SPECIFIC SERUM
ANTIMULLERIAN HORMONE CONCENTRATIONS BETWEEN
YOUNG INFERTILE WOMEN AND OOCYTE DONORS.
M. Bustillo1 , C. Goodman2 , J. Cortes3 , S. Merchant3 , C. B. Coulam2 .
1South Florida Institute for Reproductive Medicine, Miami, FL;
2 3 Reproductive Medicine Institute, Evanston, IL; Unilab, Fort
Lauderdale, FL.
P-311 BMI INFLUENCES THE IMPACT OF ORAL
CONTRACEPTIVE PILLS AND GnRH AGONISTS ON ANTRAL
FOLLICLE COUNT (AFC) OVARIAN RESERVE SCREENS.
A. K. Parker, N. Grindler, E. S. Jungheim, R. R. Odem, V. S. Ratts,
A. R. Cooper. Obstetrics & Gynecology, Division of Reproductive
Endocrinology & Infertility, Washington University, St. Louis, MO.
P-312 THE ROLE OF ANTI-MULLERIAN HORMONE
MEASUREMENT IN THE PREDICTION OF RESPONSE TO
CONTROLLED OVARIAN STIMULATION: COMPARISON WITH THE
ANTRAL FOLLICLE COUNT.
T. Habara, R. Hirata, Y. Aoi, S. Terada, N. Yoshioka, N. Hayashi.
Infertility, Okayama Couple’s Clinic, Okayama, Japan.
P-313 AGE AS DETERMINANT OF IN VITRO FERTILIZATION
(IVF) OUTCOME WITH EXTREMELY LOW ANTI- MÜLLERIAN
HORMONE (AMH).
A. Weghofer1,2,3 . 1Center for Human Reproduction, New York, NY;
2 3 Foundation for Reproductive Medicine, New York, NY; Department
of Obstetrics and Gynecology, Medical University Vienna, Wien,
Austria.
P-314 PATIENTS WITH DISCORDANT AMH AND FSH HAVE A
BETTER PROGNOSIS IN IN VITRO FERTILIZATION THAN THOSE
WITH TWO ABNORMAL MARKERS OF OVARIAN RESERVE.
T. Molinaro1 , A. Samara2 . 1Reproductive Medicine Associates of
New Jersey, Morristown, NJ; 2Department of OBGYN, Morristown
Memorial Hospital, Morristown, NJ.
P-315 REPRODUCTIVE AGED WOMEN WITH CANCER HAVE A
LOWER ANTRAL FOLLICLE COUNT THAN EXPECTED.
E. Ebbel, A. Katz, C.-N. Kao, M. Cedars. Obstetrics, Gynecology and
Reproductive Sciences, University of California, San Francisco, San
Francisco, CA.
POSTER PRESENTATIONS
156
P-316 PREDICTIVE VALUE OF ANTRAL FOLLICLE COUNT
AMONG ANONYMOUS OOCYTE DONORS IN AN EGG-
SHARING DONOR PROGRAM.
C. Boggino, G. Fiszbajn, A. Coscia, B. Riestra, S. Papier, C. E. Sueldo.
CEGYR, Center for Studies in Gynecology and Reproduction,
Buenos Aires, Argentina.
P-317 VARIATIONS IN ANTIMULLERIAN HORMONE (AMH)
LEVEL MEASUREMENTS BASED ON METHOD OF COLLECTION
AND TIME LAPSE BETWEEN COLLECTION AND ANALYSIS.
B. J. Stegmann 1 , E. M. Smith 1,2 , S. Hunter 1 , D. Santillan 1 . 1 Department
of Obstetrics and Gynecology, University of Iowa Hospitals and
Clinics, Iowa City, IA; 2 Department of Epidemiology, University of
Iowa, Iowa City, IA.
P-318 BASAL SERUM TESTOSTERONE PREDICT OVARIAN
RESPONSE AND IN VITRO FERTILIZATION OUTCOME IN WOMEN
WITH DIMINISHED OVARIAN RESERVE.
Q. Lu, H. Shen, L. Wei, C. Wang, Y. Liu, D. Lin. Reproductive Medical
Center, Peking University, People’s Hospital, Beijing, China;
Gynecology and Obstetrics, Peking University, People’s Hospital,
Beijing, China.
P-319 DOES PELVIC TUBERCULOSIS AFFECTS THE OVARIAN
RESERVE AND THE OOCYTE YIELD IN PATIENTS UNDERGOING
IN-VITRO FERTILISATION.
K. D. Nayar, P. Gupta, P. Dahiya, S. Ved, G. Kant. Akanksha IVF
Centre, Mata Chanan Devi Hospital, New Delhi, Delhi, India.
P-320 THE ROLE OF COMBINED ANTI-MULLERIAN HORMONE
AND ANTRAL FOLLICLE COUNT ASSESSMENT IN PREDICTING
CYCLE OUTCOMES IN CANCER PATIENTS UNDERGOING
CONTROLLED OVARIAN STIMULATION FOR FERTILITY
PRESERVATION.
E. Arslan1 , M. Karsy1,2 , F. Moy1,2 , K. Oktay1,3 . 1Department of Obstetrics
& Gynecology, Institute for Fertility Preservation, Laboratory of
Molecular Reproduction, New York Medical College, Valhalla, NY;
2Department of Pathology, New York Medical College, Valhalla, NY;
3Department of Cell Biology & Anatomy, New York Medical College,
Valhalla, NY.
P-321 USE OF ANTI-MULLERIAN HORMONE (AMH) AND
THREE-DIMENSIONAL TRANSVAGINAL ANTRAL FOLLICULAR
COUNT (AFC) AS BIO-MARKERS IN PREDICTING OVARIAN
RESERVE / RESPONSE IN WOMEN UNDERGOING IN-VITRO
FERTILISATION.
M. S. Hendricks, J. Chan, M. P. Paing, L. W. Khin, B. C. Tai, S. F. Loh.
KKWCH, Singapore, Singapore; National University Health Systems,
Singapore, Singapore.
__________________________________________________________
CANCER
P-322 BREAST CANCER PATIENTS HAVE LOWER RATES OF
CONTRACEPTION USE.
H. Cook-Andersen1 , S. Komrokian2 , A. DeMichele2 , H. I. Su1 .
1Reproductive Medicine, University of California, San Diego, La Jolla,
CA; 2University of Pennsylvania, Philadelphia, PA.
P-323 FEMALE CANCER SURVIVORS ARE AT HIGH RISK
FOR CYCLE CANCELATION AND HAVE REDUCED SUCCESS
COMPARED TO OTHER INFERTILITY PATIENTS IN ASSISTED
REPRODUCTIVE TECHNOLOGY (ART).
S. E. Barton 1 , S. A. Missmer 1,2,3 , K. F. Berry 1 , E. S. Ginsburg 1 . 1 Division of
Reproductive Medicine; Department of Obstetrics, Gynecology,
and Reproductive Biology, Brigham and Women’s Hospital and
Harvard Medical School, Boston, MA; 2 Channing Laboratory,
Department of Medicine, Brigham and Women’s Hospital and
Harvard Medical School, Boston, MA; 3 Department of Epidemiology,
Harvard School of Public Health, Boston, MA.